The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies

• Published in: BMC veterinary research Vol. 15; no. 1; p. 65
• Main Authors: Meier, A., de Laat, M., Reiche, D., Fitzgerald, D., Sillence, M.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.02.2019; BioMed Central; BMC
• Subjects: adverse effects; Animals; Biochemistry; Blood glucose; Blood glucose tests; blood serum; body condition; Body fat; body weight; Carbohydrates; Diabetes; Diabetes therapy; Diet; Drug therapy; Equine metabolic syndrome; Fasting; Fat body; Glucose; Glucose transport; Health aspects; Hematology; Horse Diseases - blood; Horse Diseases - drug therapy; Horses; Hyperinsulinemia; Hyperinsulinism - blood; Hyperinsulinism - drug therapy; Hyperinsulinism - veterinary; Hypoglycemia; Hypoglycemic agents; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - blood; Insulin resistance; Laminitis; Metabolic diseases; Metabolic syndrome; Metabolites; monitoring; Nitriles - therapeutic use; Novels; Ponies; Random Allocation; risk; Safety; Sodium; Sodium-glucose linked transport inhibitor; Studies; Testing; Treatment Outcome; Germany; Sodium-glucose linked transport inhibitor; Equine metabolic syndrome; Laminitis; Insulin

A previous six-week (wk) study demonstrated the potential of the sodium-glucose linked transport inhibitor velagliflozin as a novel treatment for equine insulin dysregulation. The present study examined the safety and efficacy of velagliflozin over 16 wk. of treatment, and over 4 wk. of withdrawal....